Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Breast cancer quantitative proteome and proteogenomic landscape

Open access
Johansson, Henrik J., Socciarelli, Fabio, Vacanti, Nathaniel M., Haugen, Mads H., Zhu, Yafeng, Siavelis, Ioannis, Fernandez-Woodbridge, Alejandro, Aure, Miriam R., Sennblad, Bengt, Vesterlund, Mattias, Branca, Rui M., Orre, Lukas M., Huss, Mikael, Fredlund, Erik, Beraki, Elsa, Garred, Øystein, Boekel, Jorrit, Sauer, Torill, Zhao, Wei, Nord, Silje, Höglander, Elen K., Jans, Daniel C., Brismar, Hjalmar, Haukaas, Tonje H., Bathen, Tone F., Schlichting, Ellen, Naume, Bjørn, Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Geisler, Jürgen, Hofvind, Solveig, Engebråten, Olav, Geitvik, Gry Aarum, Langerød, Anita, Kåresen, Rolf, Mælandsmo, Gunhild Mari, Sørlie, Therese, Skjerven, Helle Kristine, Park, Daehoon, Hartman-Johnsen, Olaf-Johan, Luders, Torben, Borgen, Elin, Kristensen, Vessela N., Russnes, Hege G., Lingjærde, Ole Christian, Mills, Gordon B., Sahlberg, Kristine K., Børresen-Dale, Anne-Lise, Lehtiö, Janne · 2019 · Nature Communications

Abstract

In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research and therapeutic approaches. Presented herein, an unbiased analysis of breast tumor proteomes, inclusive of 9995 proteins quantified across all tumors, for the first time recapitulates BC subtypes. Additionally, poor-prognosis basal-like and luminal B tumors are further subdivided by immune component infiltration, suggesting the current classification is incomplete. Proteome-based networks distinguish functional protein modules for breast tumor groups, with co-expression of EGFR and MET marking ductal carcinoma in situ regions of normal-like tumors and lending to a more accurate classification of this poorly defined subtype. Genes included within prognostic mRNA panels have significantly higher than average mRNA-protein correlations, and gene copy number alterations are dampened at the protein-level; underscoring the value of proteome quantification for prognostication and phenotypic classification. Furthermore, protein products mapping to non-coding genomic regions are identified; highlighting a potential new class of tumor-specific immunotherapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09018-y

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 31

  1. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000). · DOI · Paper page
  2. Senkus, E. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl 5), v8–30 (2015). · DOI · Paper page
  3. Coates, A. S. et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 26, 1533–1546 (2015). · DOI · Paper page
  4. Tyanova, S. et al. Proteomic maps of breast cancer subtypes. Nat. Commun. 7, 10259 (2016). · DOI · Paper page
  5. Akbani, R. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014). · DOI · Paper page
  6. Dennison, J. B. et al. High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype. Clin. Cancer Res. 22, 5068–5078 (2016). · DOI
  7. Nesvizhskii, A. I. Proteogenomics: concepts, applications and computational strategies. Nat. Methods 11, 1114–1125 (2014). · DOI · Paper page
  8. Branca, R. M. M. et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59–62 (2014). · DOI · Paper page
  9. Zhu, Y. et al. Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow. Nat. Commun. 9, 903 (2018). · DOI
  10. Aure, M. R. et al. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Res. 19, 44 (2017). · DOI
  11. Aure, M. R. et al. Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. Genome Med. 7, 21 (2015). · DOI
  12. Granholm, V. et al. Fast and accurate database searches with MS-GF + Percolator. J. Proteome Res. 13, 890–897 (2014). · DOI
  13. Boekel, J. et al. Multi-omic data analysis using Galaxy. Nat. Biotechnol. 33, 137–139 (2015). · DOI · Paper page
  14. Haukaas, T. H. et al. Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab. 4, 12 (2016). · DOI
  15. Prat, A. et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J. Natl. Cancer. Inst. 106, dju152 (2014). · DOI · Paper page
  16. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009). · DOI · Paper page
  17. Warburg, O. & Minami, S. Versuche an Überlebendem Carcinom-gewebe. Klin. Wochenschr. 2, 776–777 (1923). · DOI · Paper page
  18. Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750–2767 (2011). · DOI · Paper page
  19. S. Soderquist, R., Soderquist, R. S. & Eastman, A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol. Cancer Ther. 15, 2011–2017 (2016). · DOI
  20. Kim, Y. J. et al. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int. J. Cancer 134, 2424–2436 (2014). · DOI
  21. Li, J. et al. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell. 31, 225–239 (2017). · DOI · Paper page
  22. Kim, W. et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44, 325–340 (2011). · DOI · Paper page
  23. Gonçalves, E. et al. Widespread post-transcriptional attenuation of genomic copy-number variation in cancer. Cell Syst. 5, 386–398.e4 (2017). · DOI
  24. Myhre, S. et al. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol. Oncol. 7, 704–718 (2013). · DOI
  25. Eswaran, J. et al. Transcriptomic landscape of breast cancers through mRNA sequencing. Sci. Rep. 2, 264 (2012). · DOI
  26. FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature 507, 462–470 (2014). · DOI · Paper page
  27. Fritsch, C. et al. Genome-wide search for novel human uORFs and N-terminal protein extensions using ribosomal footprinting. Genome Res. 22, 2208–2218 (2012). · DOI · Paper page
  28. O’Donnell, T. J. et al. MHCflurry: open-source class I MHC binding affinity prediction. Cell Syst. 7, 129–132.e4 (2018). · DOI · Paper page
  29. Cardoso, F. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375, 717–729 (2016). · DOI · Paper page
  30. Manza, L. L., Stamer, S. L., Ham, A.-J. L., Codreanu, S. G. & Liebler, D. C. Sample preparation and digestion for proteomic analyses using spin filters. Proteomics 5, 1742–1745 (2005). · DOI · Paper page
  31. Savitski, M. M., Wilhelm, M., Hahne, H., Kuster, B. & Bantscheff, M. A scalable approach for protein false discovery rate estimation in large proteomic data sets. Mol. Cell. Proteom. 14, 2394–2404 (2015). · DOI · Paper page

Cited by

See all 235

Metadata

Authors
Johansson, H. J., Socciarelli, F., Vacanti, N. M., Haugen, M. H., Zhu, Y., Siavelis, I., Fernandez-Woodbridge, A., Aure, M. R., Sennblad, B., Vesterlund, M., Branca, R. M., Orre, L. M., Huss, M., Fredlund, E., Beraki, E., Garred, Ø., Boekel, J., Sauer, T., Zhao, W., Nord, S., Höglander, E. K., Jans, D. C., Brismar, H., Haukaas, T. H., Bathen, T. F., Schlichting, E., Naume, B., Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Geisler, J., Hofvind, S., Engebråten, O., Geitvik, G. A., Langerød, A., Kåresen, R., Mælandsmo, G. M., Sørlie, T., Skjerven, H. K., Park, D., Hartman-Johnsen, O.-J., Luders, T., Borgen, E., Kristensen, V. N., Russnes, H. G., Lingjærde, O. C., Mills, G. B., Sahlberg, K. K., Børresen-Dale, A.-L., & Lehtiö, J.
Venue
Nature Communications
Published
2019-04-08
Volume
10
Issue
1
Pages
1600-1600
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2931990777
Cited by
235
References
9
FWCI
8.71
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast cancer quantitative proteome and proteogenomic landscape. https://app.cochat.ai/papers/10.1038/s41467-019-09018-y
The paper
Johansson, H. J., Socciarelli, F., Vacanti, N. M., Haugen, M. H., Zhu, Y., Siavelis, I., Fernandez-Woodbridge, A., Aure, M. R., Sennblad, B., Vesterlund, M., Branca, R. M., Orre, L. M., Huss, M., Fredlund, E., Beraki, E., Garred, Ø., Boekel, J., Sauer, T., Zhao, W., . . . Lehtiö, J. (2019). Breast cancer quantitative proteome and proteogenomic landscape. Nature Communications. https://doi.org/10.1038/s41467-019-09018-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.